venBio Sends Letter to Immunomedics Stockholders
Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results
venBio Takes Steps to Protect Rights of Immunomedics Stockholders
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics , Inc. and Encourages Investors with Losses to Contact the Firm
venBio Comments on Immunomedics Partnership Announcement
This Gold-rated fund is a fine vehicle for new investors to gain access to the Primecap managers.
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.